Aspira Pathlab & Diagnostics Limited
Registered. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086
Corporate Office: 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086
CIN: L85100MH1973PLC289209

Date: August 12, 2025

To,
Listing Department
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001.

Security Code: 540788
Security ID: ASPIRA

Sub: Outcome of Board Meeting held on Tuesday, August 12, 2025

Dear Sir/Madam,

In compliance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company, at its Meeting held today, i.e. on Tuesday, August 12, 2025 inter alia, has considered, approved and taken on record the following matter(s):

1. Un-Audited Standalone & Consolidated Financial Results along with Limited Review Report for the first quarter ended June 30, 2025 ("the financial results") duly reviewed and approved by the Audit Committee and Board of Directors as per regulation 33 of the Listing Regulations is attached herewith.

2. Appointment of Dr. Alaka Keshav Deshpande, (DIN: 11238406) as Additional Woman Independent Director of the Company, subject to the member's approval in the ensuing Annual General Meeting by special resolution.

   Additional details pursuant to regulation 30 of the SEBI(LODR) Regulations, 2015 read with the SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is enclosed herewith in **Annexure-1.**

   Kindly note that Board Meeting commenced at 01.45 P.M (IST) and concluded at 05.00 P.M.(IST)

   The above information is being made available on the website of the Company www.aspiradiagnostics.com.

   We request you to kindly take the same on your record.

   Thanking you.

   Yours Faithfully,

For and on behalf of
Aspira Pathlab & Diagnostics Limited

Nikunj Velji Mange
Digitally signed by Nikunj Velji Mange
Date: 2025.08.12 17:10:22 +05'30'

_____

Nikunj Mange
Executive Director

Aspira Pathlab & Diagnostics Limited
Registered. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086
Corporate Office: 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086
CIN: L85100MH1973PLC289209

CERTIFIED TRUE COPY OF THE RESOLUTION PASSED BY THE BOARD OF DIRECTORS OF ASPIRA PATHLAB & DIAGNOSTICS LIMITED ("THE COMPANY") IN ITS MEETING HELD ON TUESDAY, AUGUST 12, 2025 COMMENCED AT 01.45 P.M (IST) AT UNIT 6 & 7, GROUND FLOOR, BHAVESHWAR ARCADE PREMISES CO-OP. SOCIETY LTD, NITYANAND NAGAR, GHATKOPAR WEST, MUMBAI, MAHARASHTRA 400086.

AUTHORISATION FOR SIGNING OF THE UNADUITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED JUNE 30, 2025

"**RESOLVED THAT** pursuant to regulation 33(2)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the unaudited standalone & consolidated financial results for the first quarter ended June 30,2025 be and is hereby approved.

RESOLVED FURTHER THAT pursuant to regulation 33(2)(b) of the SEBI (LODR) Regulations, 2015, Mr. Nikunj Mange, Executive Director (DIN: 08489442) of the Company be and is hereby authorised on behalf of the Board members to sign the aforesaid unaudited standalone & consolidated financial results for the first quarter ended June 30, 2025".

For and on behalf of
Aspira Pathlab & Diagnostics Limited

Pankaj Jashwant Shah
Digitally signed by Pankaj Jashwant Shah
Date: 2025.08.12 17:09:31 +05'30'

Pankaj Shah
Managing Director & CEO

Sarda Soni Associates LLP

CHARTERED ACCOUNTANTS

Manoj Jain

B.Com(H), FCA, ACS, IP(ICAI), RV(S&FA)

Limited Review Report on unaudited standalone financial results of Aspira Pathlab and Diagnostics Limited for the quarter ended 30TH June, 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Aspira Pathlab & Diagnostics Limited

We have reviewed the accompanying statement of **Unaudited Standalone Financial Results of Aspira Pathlab & Diagnostics Limited** (hereinafter referred to as "the Company") for the quarter ended 30th June, 2025 (the Statement'), being submitted by the company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

This Statement, which is the responsibility of the company's management and approved by the company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting' ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of the company's personnel and analytical procedures applied to financial data and thus provide less assurance than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the accounting principles laid down in Ind AS 34 prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI LODR Regulations 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

SARDA SONI ASSOCIATES LLP. FIRM REGN. NO.117235 MUMBAI CHARTERED ACCOUNTANTS

11, Friend's Union Premises Co-operative Society Ltd., 2nd Floor, 227, P. D'Mello Road, Mumbai 400 001.
Phone: 022-2269 5289 ; Mobile: 98191 65816
Email: ssaaudit2102@gmail.com / sardasoniassociates2102@gmail.com
Nagpur (HO): "Chartered Square", Samrat Ashok Square, Saraipeth, Nagpur 400 009.
Phone: 0712-2726795, 2729471

Sarda Soni Associates LLP

CHARTERED ACCOUNTANTS

Manoj Jain

B.Com(H), FCA, ACS, IP(ICAI), RV(S&FA)

Note : The Company acquired the business undertaking of Aspira DNA Diagnostics Gujarat LLP on a slump sale basis for a consideration of Rs. 13.00 Lacs, effective from the end of the business day on 30th June, 2025 pursuant to a Business Transfer Agreement.

For **SARDA SONI ASSOCIATES LLP**
Chartered Accountants
Firm Reg. No. 117235W

(MANOJ KUMAR JAIN)
Partner
Membership No.- 120788
UDIN : **25120788BMIEHC9984**

Place- Mumbai
Date- 12.08.2025

11, Friend's Union Premises Co-operative Society Ltd., 2nd Floor, 227, P. D'Mello Road, Mumbai 400 001.
Phone: 022-2269 5289 ; Mobile: 98191 65816
Email: ssaaudit2102@gmail.com / sardasoniassociates2102@gmail.com
Nagpur (HO): "Chartered Square", Samrat Ashok Square, Saraipeth, Nagpur 400 009.
Phone: 0712-2726795, 2729471

Aspira Pathlab & Diagnostics Limited
(CIN L85100MH1973PLC289709)
Reg. Office : Flat No. 2, R.D. Shah Bldg., Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai 400086
Statement of Standalone Financial Results for the Quarter ended 30th June 2025

(Rs. in Lakhs)

Particulars	Quarter ended			Year ended
	30-Jun-25	31-Mar-25	30-Jun-24	31-Mar-25
	(Unaudited) (Refer Note 3)	(Unaudited) (Refer Note 3)	(Unaudited) (Refer Note 3)	(Audited)
1. Income				
(a) Revenue from Operations				
Sales/Income from Operations	524.80	577.67	463.73	2,199.90
(b) Other Income	10.77	13.04	9.18	38.89
Total income	535.57	590.71	472.91	2,238.79
2. Expenses				
(a) Cost of Materials consumed	89.60	86.95	88.03	369.58
(b) Laboratory Testing Charges	27.42	25.09	26.00	99.65
(c) Employee benefits expense	189.01	194.41	166.23	732.67
(d) Finance Costs	9.40	9.32	8.12	34.74
(d)Depreciation and amortisation expense	36.52	36.74	37.66	149.38
(e)Other expenses	136.67	165.87	148.54	645.57
Total Expenses	488.63	518.37	474.58	2,031.53
3. Profit / (Loss) before exceptional items and tax (1-2)	46.94	72.33	(1.67)	207.26
4. Exceptional Items	-	-	-	-
5. Profit / (Loss) before tax (3+4)	46.94	72.33	(1.67)	207.26
6. Tax Expenses	-	-	-	-
7. Profit / (Loss) after tax (5-6)	46.94	72.33	(1.67)	207.26
8. Other Comprehensive income(net of tax)		0.04		0.04
9. Total Comprehesive income (7+8)	46.94	72.37	(1.67)	207.30
10. Paid up Equity share capital (Face value of Rs.10/- each)	1,029.30	1,029.30	1,029.30	1,029.30
11. Other equity				192.34
12. Earning per share				
(a) Basic	0.46	0.70	(0.02)	2.01
(b) Diluted	0.46	0.70	(0.02)	2.01

Note

1. The above Standalone financial results of the Company were reviewed and recommended by the Audit Committee and approved by the Board of Directors in their respective meetings held on 12.08.2025. The statutory auditors of the Company have expressed an unmodified opinion thereon.

2. The Standalone financial results of the Company have been prepared in accordance with Indian Accounting standards (Ind AS) as notified by the Ministry of Corporate Affairs and prescribed under Section 133 of the Companies Act 2013 read with Companies (Indian Accounting Standard) Rules, 2015, and in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and other accounting principles generally accepted in India, to the extent applicable.

3. The Standalone figures for the quarter ended 31 March 2025 are the balancing figures between audited figures in respect of full financial year and the published year to date unaudited figures up to the third quarter ended 31 December 2024, which was subjected to limited review.

4. the Board of Directors of the Company, which has been identified as being the Chief operating decision maker, evaluates the Company's performance allocates resources based on the analysis of the various performance indicators of the Company as a single unit.Therefore, there is no reportable segment of the Company in accordance with requirement of Ind AS 108 - Operating Segment, notified under the Companies (Indian Accounting Standard) Rules, 2015.

5.The Company acquired the business undertaking of Aspira DNA Diagnostics Gujarat LLP on a slump sale basis for a consideration of ₹13.00 lakhs, effective from the end of business day on 30th June 2025, pursuant to a Business Transfer Agreement.

6. The previous period figures have been regrouped/reclassified wherever required to make them comparable with the figure of the current period.

FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED

Nikunj Velji Mange

Nikunj Mange
Executive Director

DIN: 08489447

Place : Mumbai
Date : 12.08.2025

SARDA SONI ASSOCIATES LLP * CHARTERED ACCOUNTANTS * FIRM REGN. NO.117235 MUMBAI

FOR SARDA SONI ASSOCIATES LLP
CHARTERED ACCOUNTANTS

(MANOJ KUMAR JAIN)
PARTNER
M. No.120788

Sarda Soni Associates LLP

CHARTERED ACCOUNTANTS

Manoj Jain

B.Com(H), FCA, ACS, IP(ICAI), RV(S&FA)

Limited Review Report on unaudited consolidated financial results of Aspira Pathlab & Diagnostics Limited for the quarter ended 30th June, 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Aspira Pathlab & Diagnostics Limited

We have reviewed the accompanying Statement of **Unaudited Consolidated Financial Results** of **Aspira Pathlab & Diagnostics Limited** (hereinafter referred to as "the Parent'), and its associates (the Parent and its associates together referred to as "the Group") for the quarter ended 30th June, 2025 (the Statement'), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting' ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review..

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the associate "Aspira DNA Diagnostics Gujarat LLP".

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI LODR Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



11, Friend's Union Premises Co-operative Society Ltd., 2nd Floor, 227, P. D'Mello Road, Mumbai 400 001.
Phone: 022-2269 5289 ; Mobile: 98191 65816
Email: ssaaudit2102@gmail.com / sardasoniassociates2102@gmail.com
Nagpur (HO): "Chartered Square", Samrat Ashok Square, Saraipeth, Nagpur 400 009.
Phone: 0712-2726795, 2729471

Sarda Soni Associates LLP

CHARTERED ACCOUNTANTS

Manoj Jain

B.Com(H), FCA, ACS, IP(ICAI), RV(S&FA)

The accompanying unaudited consolidated financial results include the Holding Company's share of net loss after tax for the quarter ended June 30, 2025, as considered in the unaudited consolidated financial results, in respect of the associate based on their interim financial information which has not been reviewed by their auditor. This unaudited financial information has been approved and furnished to us by the management. Our conclusion, in so far as it relates to the affairs of this associate, is based solely on such unaudited financial information. According to the information and explanations given to us by the Management, these interim financial statements / financial information / financial results are not material to the Company. Our conclusion on the Statement is not modified in respect of the above matter.

Note : The Company acquired the business undertaking of Aspira DNA Diagnostics Gujarat LLP on a slump sale basis for a consideration of Rs. 13.00 Lacs, effective from the end of the business day on 30th June, 2025 pursuant to a Business Transfer Agreement.

SARDA SONI ASSOCIATES LLP ★ CHARTERED ACCOUNTANTS ★ FIRM REGN. NO.117235 MUMBAI

For **SARDA SONI ASSOCIATES LLP**
Chartered Accountants
Firm Reg. No. 117235W

(MANOJ KUMAR JAIN)
Partner
Membership No.- 120788
UDIN : **25120788BMIEHE7517**

Place- Mumbai
Date- 12.08.2025

11, Friend's Union Premises Co-operative Society Ltd., 2nd Floor, 227, P. D'Mello Road, Mumbai 400 001.
Phone: 022-2269 5289 ; Mobile: 98191 65816
Email: ssaaudit2102@gmail.com / sardasoniassociates2102@gmail.com
Nagpur (HO): "Chartered Square", Samrat Ashok Square, Saraipeth, Nagpur 400 009.
Phone: 0712-2726795, 2729471

Aspira Pathlab & Diagnostics Limited

(CIN L85100MH1973PLC289209)

Reg. Office : Flat No. 2, R.D. Shah Bldg., Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai -400086

Statement of Consolidated Financial Results for the Quarter ended 30th June 2025

(Rs. in Lakhs)

Particulars	Quarter ended			Year ended
	30-Jun-25	31-Mar-25	30-Jun-24	31-Mar-25
	(Unaudited) (Refer Note 3)	(Unaudited) (Refer Note 3)	(Unaudited) (Refer Note 3)	(Audited)
1. Income				
(a) Revenue from Operations				
Sales/Income from Operations	524.80	577.67	463.73	2,199.90
(b) Other Income	10.77	13.04	9.18	38.89
Total income	**535.57**	**590.71**	**472.91**	**2,238.79**
2. Expenses				
(a) Cost of Materials consumed	89.60	86.95	88.03	369.58
(b) Laboratory Testing Charges	27.42	25.09	26.00	99.65
(c) Employee benefits expense	189.01	194.41	166.23	732.62
(d) Finance Costs	9.40	9.32	8.12	34.74
(d)Depreciation and amortisation expense	36.52	36.74	37.66	149.38
(e)Other expenses	136.67	165.87	148.54	645.57
Total Expenses	**488.63**	**518.37**	**474.58**	**2,031.53**
3. Profit / (Loss) before exceptional items and tax (1-2)	**46.94**	**72.33**	**(1.67)**	**207.26**
4. Exceptional Items	-	-	-	
5. Share of profit of associates, net of tax	(4.79)	(4.27)	6.38	(5.00)
6. Profit / (Loss) before tax (3+4+5)	**42.15**	**68.06**	**4.71**	**202.26**
7. Tax Expenses	-	-	-	
8. Profit / (Loss) after tax (6-7)	**42.15**	**68.06**	**4.71**	**202.26**
9. Other Comprehensive income(net of tax)		0.04		0.04
10. Total Comprehesive income (8+9)	42.15	68.10	4.71	202.31
11. Paid up Equity share capital (Face value of Rs.10/- each)	1,029.30	1,029.30	1,029.30	1,029.30
12. Other equity				187.34
13. Earning per share				
(a) Basic	0.41	0.66	0.05	1.97
(b) Diluted	0.41	0.66	0.05	1.97

Note

1. The above consolidated financial results of the Company were reviewed and recommended by the Audit Committee and approved by the Board of Directors in their respective meetings held on 12.08.2025. The Statutory auditors of the Holding Company have conducted "Limited Review" of the said consolidated financial results for the quarter ended June 30, 2025. The statutory auditors of the Company have expressed an unmodified opinion thereon.

2. The consolidated financial results of the Company have been prepared in accordance with Indian Accounting standards (Ind AS) as notified by the Ministry of Corporate Affairs and prescribed under Section 133 of the Companies Act 2013 read with Companies (Indian Accounting Standard) Rules, 2015, and in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and other accounting principles generally accepted in India, to the extent applicable.

3. The Consolidated figures for the quarter ended 31 March 2025 are the balancing figures between audited figures in respect of full financial year and the published year to date unaudited figures up to the third quarter ended 31 December 2024, which was subjected to limited review.

SARDA SONI ASSOCIATES LLP. FIRM REGN. NO. 117235 MUMBAI CHARTERED ACCOUNTANTS

4.The above consolidated financial results represent consolidated results of the Company and Its associates (together referred to as 'the Group').

5. The Board of Directors of the Holding Company, which has been identified as being the Chief operating decision maker, evaluates the Holding Company's performance allocates resources based on the analysis of the various performance indicators of the Holding Company as a single unit.Therefore, there is no reportable segment of the Holding Company in accordance with requirement of Ind AS 108 - Operating Segment, notified under the Companies (Indian Accounting Standard) Rules, 2015.

6. The Company acquired the business undertaking of Aspira DNA Diagnostics Gujarat LLP, an associate, on a slump sale basis for ₹13.00 lakhs effective from the end of business day on 30th June 2025 pursuant to a Business Transfer Agreement.

7. The previous period figures have been regrouped/reclassified wherever required to make them comparable with the figure of the current period.

FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED

Nikunj Velji Mange

Nikunj Mange
Executive Director

DIN. 08489442

Place : Mumbai
Date : 12.08.2025

SARDA SONI ASSOCIATES LLP ★ FIRM REGN. NO.117235 MUMBAI ★ CHARTERED ACCOUNTANTS

FOR SARDA SONI ASSOCIATES LLP
CHARTERED ACCOUNTANTS

(MANOJ KUMAR JAIN)
PARTNER
M. No.120788

Aspira Pathlab & Diagnostics Limited
Registered. Office: Flat No. 2, R D Shah Building, Shraddhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai-400086
Corporate Office: 6 & 7, Bhaveshwar Arcade, Near Shreyas Junction LBS Marg, Behind Saraswat Bank, Ghatkopar (W), Mumbai-400086
CIN: L85100MH1973PLC289209

Annexure-1

Disclosure pursuant to SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

Sr. no.	Particulars	Disclosure
1.	Name of Director	Dr. Alaka Keshav Deshpande (DIN: 11238406)
2.	Reason of Change-Appointment	Appointed as an Additional Independent Director, designated as 'Woman Independent Director' of the Company.
3.	Date of appointment & term of appointment	September 27, 2025 Term of three (3) years i.e September 27, 2025 till September 26, 2028
4.	Brief Profile	Dr. Alaka Keshav Deshpande holds an MBBS and an M.D. in General Medicine & Therapeutics from Mumbai University. She has undergone specialized training in Nuclear Medicine at Bhabha Atomic Research Centre, Ultra-Sonography in Mumbai, and Gastrointestinal Endoscopies at AIIMS, New Delhi. Additionally, she has completed a Certificate Course in Diagnosis, Clinical Management, and Counselling in AIDS conducted by WHO/NACO/CMAI, New Delhi. Over the course of her distinguished career, Dr. Deshpande has served as Professor and Head of the Department of Medicine and Director of the Centre of Excellence in HIV Care. She was associated with Grant Medical College and Sir J.J. Group of Government Hospitals, Byculla, as an M.D. Professor. She has also contributed as a Sectional Editor for the API Textbook of Medicine and held the position of Chairperson of the Ethics Committee at Hinduja Hospital.
5.	Disclosure of relationships between Directors	Dr. Deshpande is not related to any other Director or Key Managerial Personnel (KMP) of the Company.
6.	Information as required pursuant to BSE Circular with ref. no. LIST/COMP/14/2018-19 regarding the Director not being debarred from holding the office by virtue of any SEBI order or any other such authority.	Dr. Deshpande is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.